Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease

We recently published a case series of typically commensal Neisseria spp. disease among eculizumab recipients.1 Eculizumab is a terminal complement inhibitor indicated for treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and certain patients with generalized myasthenia gravis or neuromyelitis optica spectrum disorder.2 Due to complement inhibition, many different Neisseria spp. can cause invasive disease in eculizumab recipients1, 3, 4 and eculizumab recipients are at an estimated 2000-fold increased risk of meningococcal disease (caused by Neisseria meningitidis).
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research